Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215585) titled 'AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL' on Oct. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AstraZeneca
Condition:
Large B-cell Lymphoma
Intervention:
Drug: AZD0486
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: November 2, 2025
Target Sample Size: 420
Countries of Recruitment:
Australia
Belgium
Brazil
Canada
China
Hong Kong
Japan
South Korea
Australia
Belgium
Brazil
Canada
China
Hong Kong
Japan
South Korea
To kno...